HPV

Cervical Neoplasia Incidence After HPV Vaccination

Cervical Neoplasia Incidence After HPV Vaccination

By

Decreases in cervical intraepithelial neoplasia (CIN) on the population level among patients vaccinated for the human papillomavirus (HPV) should be considered.

Parents Support Mandatory School-entry HPV Vaccination With Opt-out Provisions

Parents Support Mandatory School-entry HPV Vaccination With Opt-out Provisions

By

Only 1 in 5 parents support laws requiring human papillomavirus (HPV) vaccination for school attendance.

Immunogenicity of HPV Vaccination With 1 to 3 Doses Assessed

Immunogenicity of HPV Vaccination With 1 to 3 Doses Assessed

By

Researchers found that vaccination for HPV should be given in 2 doses, at least 6 months apart for routine vaccinations of young girls.

HPV Vaccine Still Effective with Fewer Than Three Doses

HPV Vaccine Still Effective with Fewer Than Three Doses

By

The human papillomavirus (HPV)-16/18 vaccine appears to protect against the viral strain even after one or two doses.

Many Students Mistakenly Believe HPV Risk is Low

Many Students Mistakenly Believe HPV Risk is Low

Many American college students don't fully understand the threat posed by the human papillomavirus (HPV) or their risk for infection.

HPV Vaccination in Females May Indirectly Benefit Males

HPV Vaccination in Females May Indirectly Benefit Males

Males benefit indirectly when girls are immunized against human papillomavirus (HPV).

In Teen Boys, HPV4 Vaccine Cost-Effective for Oropharyngeal Prevention

In Teen Boys, HPV4 Vaccine Cost-Effective for Oropharyngeal Prevention

The quadrivalent human papillomavirus (HPV4) vaccine appears to be cost-effective for the prevention of oropharyngeal cancer (OPC).

Challenges in Oropharyngeal Cancer Identified

Challenges in Oropharyngeal Cancer Identified

Mixed views in relation to explaining causal role of human papillomavirus (HPV) in oropharyngeal cancer.

Promising HPV Vaccine Receives Development Funding from the National Cancer Institute

Promising HPV Vaccine Receives Development Funding from the National Cancer Institute

The National Cancer Institute (NCI) has funded $3.5 million for the development of a new human papillomavirus (HPV) vaccine.

Human Papilloma Virus and Squamous Cell Carcinoma of the Anus

Human Papilloma Virus and Squamous Cell Carcinoma of the Anus

[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). Etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) discussed.

For HPV-Associated Anal Cancer, ADXS-HPV Immunotherapy May Be Effective

For HPV-Associated Anal Cancer, ADXS-HPV Immunotherapy May Be Effective

Results of ADXS-HPV with standard chemo and radiotherapy for HPV-associated anal cancer who have a high risk of recurrence.

For Cancer Prevention, 9-Valent HPV Vaccine Promising

For Cancer Prevention, 9-Valent HPV Vaccine Promising

Research suggests the human papillomavirus (HPV) vaccine could prevent 90 percent of cervical malignancies.

Urine Test for Cervical Human Papillomavirus (HPV) Proves Accurate

Urine Test for Cervical Human Papillomavirus (HPV) Proves Accurate

Less invasive method may increase screening rates for cervical cancer, researchers say.

Human Papillomavirus (HPV) Test May Be More Accurate Than Pap Test for Cervical Cancer Screening

Human Papillomavirus (HPV) Test May Be More Accurate Than Pap Test for Cervical Cancer Screening

By

A review of data suggests that HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.

In Canada, HPV-Related Noncervical Cancers on the Rise

In Canada, HPV-Related Noncervical Cancers on the Rise

Registry data show increase in incidence rates of HPV-related oropharyngeal and anal cancers.

HPV Vaccine Doesn't Increase VTE Risk

HPV Vaccine Doesn't Increase VTE Risk

Risk for venous thromboembolism appears to be no higher after quadrivalent HPV vaccination.

HPV Status Linked to Survival in Oropharynx Cancer

HPV Status Linked to Survival in Oropharynx Cancer

For patients with oropharynx cancer, HPV positivity is associated with improved survival after disease progression.

New HPV Test Highly Predictive of Cervical Cancer

New HPV Test Highly Predictive of Cervical Cancer

HPV test can detect 95% of precancerous lesions, and cotesting with Pap detects more disease.

Head and Neck Cancer Knowledge Low Among US Adults

Head and Neck Cancer Knowledge Low Among US Adults

Two-thirds of surveyed adults reported being not very or not at all knowledgeable about head and neck cancer.

Reduced-dose Radiation Safe for Certain Patients with Low-risk HPV-positive Oropharyngeal Cancer

Reduced-dose Radiation Safe for Certain Patients with Low-risk HPV-positive Oropharyngeal Cancer

By

CHICAGO, IL—Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.

Many Healthy People Infected With Varied HPV Strains

Many Healthy People Infected With Varied HPV Strains

Almost 70% of healthy humans infected with more than 100 strains of human papillomavirus.

Oncogenic Oral HPV Prevalent in HPV+ Oropharyngeal Cancer

Oncogenic Oral HPV Prevalent in HPV+ Oropharyngeal Cancer

Oral HPV, HPV16 DNA commonly detected in patients with oropharyngeal cancer, but not their partners.

First HPV Test for Primary Cervical Cancer Receives FDA Approval

First HPV Test for Primary Cervical Cancer Receives FDA Approval

The FDA has approved Roche's cobas HPV Test, the first human papillomavirus (HPV) DNA test for women ages >25 that can be used alone to help assess the need for additional diagnostic testing for cervical cancer.

Before HPV Vaccine, Most Oropharyngeal Cancers Were HPV+

Before HPV Vaccine, Most Oropharyngeal Cancers Were HPV+

Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus, specifically HPV 16 or 18.

ID'ing Different First Symptoms in Patients With Two Types of OPSCC

ID'ing Different First Symptoms in Patients With Two Types of OPSCC

By

Patients with HPV-positive OPSCC report different symptoms than those with HPV-negative OPSCC, which may have an effect on how early the disease is diagnosed.

FDA Panel Recommends HPV Test That Could Replace Pap

FDA Panel Recommends HPV Test That Could Replace Pap

Experts voted 13-0 that Roche's test was safe and effective as first step in cervical cancer screening.

HPV Vaccination Cuts Cervical Lesion Risk

HPV Vaccination Cuts Cervical Lesion Risk

HPV vaccination is associated with reduced risk of atypic, atypia+ or cervical intraepithelial neoplasia grade 2 or 3.

President's Panel: Increase HPV Vaccination

President's Panel: Increase HPV Vaccination

The HPV vaccine protects against cancers of the cervix, throat, rectum, and penis, but too few girls and boys are getting vaccinated.

HPV Detection Not Predictive of Cervical Precancer

HPV Detection Not Predictive of Cervical Precancer

Three-year risks of CIN 2+ and CIN+ were 0.4% and 0.0%, respectively, after infection

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs